{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:09:23Z","timestamp":1791403763978,"version":"4.3.3"},"publisher-location":"Totowa, NJ","reference-count":68,"publisher":"Humana Press","isbn-type":[{"value":"9781607614999","type":"print"},{"value":"9781607615002","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-1-60761-500-2_20","type":"book-chapter","created":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T20:48:24Z","timestamp":1267649304000},"page":"309-322","source":"Crossref","is-referenced-by-count":96,"title":["The Serotonin Hypothesis of Pulmonary Hypertension Revisited"],"prefix":"10.1007","author":[{"given":"Margaret R.","family":"MacLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Dempsie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,26]]},"reference":[{"key":"20_CR1_20","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","volume":"43","author":"G Simonneau","year":"2004","unstructured":"Simonneau G, Gali\u00e8 N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S-12S","journal-title":"J Am Coll Cardiol"},{"key":"20_CR2_20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1161\/01.CIR.100.8.869","volume":"100","author":"RB Rothman","year":"1999","unstructured":"Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates - implications for primary pulmonary hypertension. Circulation 100:869-875","journal-title":"Circulation"},{"key":"20_CR3_20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0006-2952(00)00306-3","volume":"59","author":"IH Ulus","year":"2000","unstructured":"Ulus IH, Maher TJ, Wurtman RJ (2000) Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 59:1611-1621","journal-title":"Biochem Pharmacol"},{"key":"20_CR4_20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","volume":"99","author":"P Herv\u00e9","year":"1995","unstructured":"Herv\u00e9 P, Launay JM, Scrobohaci ML et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249-254","journal-title":"Am J Med"},{"key":"20_CR5_20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0002-9343(90)90111-P","volume":"89","author":"P Herve","year":"1990","unstructured":"Herve P, Drouet L, Dosquet C et al (1990) Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 89:117-120","journal-title":"Am J Med"},{"key":"20_CR6_20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/j.1471-4159.1992.tb08356.x","volume":"59","author":"F Martin","year":"1992","unstructured":"Martin F, Artigas F (1992) Simultaneous effects of para-chloroamphetamine, D-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 59:1138-1144","journal-title":"J Neurochem"},{"key":"20_CR7_20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/jpet.107.132654","volume":"324","author":"D Zolkowska","year":"2008","unstructured":"Zolkowska D, Baumann MH, Rothman RB (2008) Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 324:791-797","journal-title":"J Pharmacol Exp Ther"},{"key":"20_CR8_20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1096\/fj.00-0431fje","volume":"15","author":"SL Lee","year":"2001","unstructured":"Lee SL, Wang WW, Fanburg BL (2001) Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J 15:1324-1325","journal-title":"FASEB J"},{"key":"20_CR9_20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0014-2999(00)00458-1","volume":"401","author":"LA Patnaude","year":"2000","unstructured":"Patnaude LA, Undem BJ, O\u2019Rourke ST (2000) Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries. Eur J Pharmacol 401:229-234","journal-title":"Eur J Pharmacol"},{"key":"20_CR10_20","doi-asserted-by":"crossref","first-page":"L662","DOI":"10.1152\/ajplung.1999.277.3.L662","volume":"277","author":"HL Reeve","year":"1999","unstructured":"Reeve HL, Archer SL, Soper M, Weir EK (1999) Dexfenfluramine increases pulmonary smooth muscle intracellular Ca2+ independent of membrane potential. Am J Physiol Lung Cell Mol Physiol 277:L662-L666","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"20_CR11_20","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/01.CIR.94.9.2216","volume":"94","author":"EK Weir","year":"1996","unstructured":"Weir EK, Reeve HL, Huang JMC, Michelakis E, Nelson DP, Hampl V et al (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216-2220","journal-title":"Circulation"},{"key":"20_CR12_20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0163-7258(02)00234-6","volume":"95","author":"RB Rothman","year":"2002","unstructured":"Rothman RB, Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88","journal-title":"Pharmacol Ther"},{"key":"20_CR13_20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/sj.bjp.0706158","volume":"144","author":"SPH Alexander","year":"2005","unstructured":"Alexander SPH, Mathie A, Peters JA (2005) Guide to receptors and channels, 1st edition (2005 revision). Br J Pharmacol 144:S1-S128","journal-title":"Br J Pharmacol"},{"key":"20_CR14_20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/j.1552-4604.1995.tb05013.x","volume":"35","author":"WH Frishman","year":"1995","unstructured":"Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B (1995) Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 35:541-572","journal-title":"J Clin Pharmacol"},{"key":"20_CR15_20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0167-5273(87)90200-2","volume":"14","author":"MD McGoon","year":"1987","unstructured":"McGoon MD, Vlietstra RE (1987) Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. Int J Cardiol 14:303-309","journal-title":"Int J Cardiol"},{"key":"20_CR16_20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/01.CIR.87.2.401","volume":"87","author":"PD MacIntyre","year":"1993","unstructured":"MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS (1993) Effect of subcutaneous sumatriptan, a selective 5Ht1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87:401-405","journal-title":"Circulation"},{"key":"20_CR17_20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1476-5381.1996.tb15982.x","volume":"119","author":"MR MacLean","year":"1996","unstructured":"MacLean MR, Clayton RA, Templeton AGB, Morecroft I (1996) Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 119:277-282","journal-title":"Br J Pharmacol"},{"key":"20_CR18_20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/sj.bjp.0702841","volume":"128","author":"I Morecroft","year":"1999","unstructured":"Morecroft I, Heeley RP, Prentice HM, Kirk A (1999) MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 128:730-734","journal-title":"Br J Pharmacol"},{"key":"20_CR19_20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nm764","volume":"8","author":"JM Launay","year":"2002","unstructured":"Launay JM, Herve P, Peoc\u2019h K et al (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135","journal-title":"Nat Med"},{"key":"20_CR20_20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0165-6147(99)01389-9","volume":"20","author":"MR MacLean","year":"1999","unstructured":"MacLean MR (1999) Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci 20:490-495","journal-title":"Trends Pharmacol Sci"},{"key":"20_CR21_20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1161\/hh2401.100426","volume":"89","author":"A Keegan","year":"2001","unstructured":"Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR (2001) Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension - converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B\/1D-receptor antagonist GR127935. Circ Res 89:1231-1239","journal-title":"Circ Res"},{"key":"20_CR22_20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1183\/09031936.03.00036203","volume":"22","author":"B Rondelet","year":"2003","unstructured":"Rondelet B, Van Beneden R, Kerbaul F et al (2003) Expression of the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 22:408-412","journal-title":"Eur Respir J"},{"key":"20_CR23_20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.RES.0000176025.57706.1e","volume":"97","author":"A Lawrie","year":"2005","unstructured":"Lawrie A, Spiekerkoetter E, Martinez EC et al (2005) Interdependent serotonin transporter and receptor pathways regulate S100A4\/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97:227-235","journal-title":"Circ Res"},{"key":"20_CR24_20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/0961203307080629","volume":"16","author":"A Kasparian","year":"2007","unstructured":"Kasparian A, Floros A, Gialafos E et al (2007) Raynaud\u2019s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16:505-508","journal-title":"Lupus"},{"key":"20_CR25_20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0014-2999(98)00520-2","volume":"355","author":"SR Bailey","year":"1998","unstructured":"Bailey SR, Elliott J (1998) Evidence for different 5-HT1B\/1D receptors mediating vasoconstriction of equine digital arteries and veins. Eur J Pharmacol 355:175-187","journal-title":"Eur J Pharmacol"},{"key":"20_CR26_20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/1529-0131(200007)43:7<1641::AID-ANR30>3.0.CO;2-Y","volume":"43","author":"E Susol","year":"2000","unstructured":"Susol E, MacGregor AJ, Barrett JH et al (2000) A two-stage, genome-wide screen for susceptibility loci in primary Raynaud\u2019s phenomenon. Arthritis Rheum 43:1641-1646","journal-title":"Arthritis Rheum"},{"key":"20_CR27_20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/0961203306069997","volume":"15","author":"S Bernatsky","year":"2006","unstructured":"Bernatsky S, Pineau CA, Lee JL, Clarke AE (2006) Headache, Raynaud\u2019s syndrome and serotonin receptor agonists in systemic lupus erythematosus. Lupus 15:671-674","journal-title":"Lupus"},{"key":"20_CR28_20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/01.RES.0000216858.04599.e1","volume":"98","author":"A Cogolludo","year":"2006","unstructured":"Cogolludo A, Moreno L, Lodi F et al (2006) Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells - role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 98:931-938","journal-title":"Circ Res"},{"key":"20_CR29_20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1164\/rccm.200302-264OC","volume":"170","author":"DJ Welsh","year":"2004","unstructured":"Welsh DJ, Harnett M, Maclean M, Peacock AJ (2004) Proliferation and signaling in fibroblasts - role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med 170:252-259","journal-title":"Am J Respir Crit Care Med"},{"key":"20_CR30_20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1124\/jpet.105.098269","volume":"317","author":"J Callebert","year":"2006","unstructured":"Callebert J, Esteve JM, Herv\u00e9 P et al (2006) Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine2B receptors in mice. J Pharmacol Exp Ther 317:724-731","journal-title":"J Pharmacol Exp Ther"},{"key":"20_CR31_20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.cardiores.2003.09.015","volume":"60","author":"C Blanpain","year":"2003","unstructured":"Blanpain C, Le Poul E, Parma J, Knoop C, Detheux M, Parmentier M et al (2003) Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60:518-528","journal-title":"Cardiovasc Res"},{"key":"20_CR32_20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrn1008","volume":"4","author":"GE Torres","year":"2003","unstructured":"Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4:13-25","journal-title":"Nat Rev Neurosci"},{"key":"20_CR33_20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI200112805","volume":"108","author":"S Eddahibi","year":"2001","unstructured":"Eddahibi S, Humbert M, Fadel E et al (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108:1141-1150","journal-title":"J Clin Invest"},{"key":"20_CR34_20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/01.CIR.0000091409.53101.E8","volume":"108","author":"S Eddahibi","year":"2003","unstructured":"Eddahibi S, Chaouat A, Morrell N et al (2003) Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108:1839-1844","journal-title":"Circulation"},{"key":"20_CR35_20","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1136\/thorax.57.2.110","volume":"57","author":"L Long","year":"2002","unstructured":"Long L, Aldashev AA, Hensiek A et al (2002) Preliminary identification of genetic loci associated with high altitude pulmonary hypertension by association mapping. Thorax 57:S110","journal-title":"Thorax"},{"key":"20_CR36_20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2006.12.011","volume":"153","author":"TP Olson","year":"2007","unstructured":"Olson TP, Snyder EM, Frantz RP, Turner ST, Johnson BD (2007) Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. Am Heart J 153:426-432","journal-title":"Am Heart J"},{"key":"20_CR37_20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1164\/rccm.200509-1365OC","volume":"173","author":"RD Machado","year":"2006","unstructured":"Machado RD, Koehler R, Glissmeyer E et al (2006) Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 173:793-797","journal-title":"Am J Respir Crit Care Med"},{"key":"20_CR38_20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1164\/rccm.200509-1361OC","volume":"173","author":"ED Willers","year":"2006","unstructured":"Willers ED, Newman JH, Loyd JE et al (2006) Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173:798-802","journal-title":"Am J Respir Crit Care Med"},{"key":"20_CR39_20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1172\/JCI8678","volume":"105","author":"S Eddahibi","year":"2000","unstructured":"Eddahibi S, Hanoun N, Lanfumey L et al (2000) Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105:1555-1562","journal-title":"J Clin Invest"},{"key":"20_CR40_20","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1161\/01.CIR.0000127375.56172.92","volume":"109","author":"MR MacLean","year":"2004","unstructured":"MacLean MR, Deuchar GA, Hicks MN et al (2004) Overexpression of the 5-hydroxytryptamine transporter gene - effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109:2150-2155","journal-title":"Circulation"},{"key":"20_CR41_20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1161\/01.RES.0000222546.45372.a0","volume":"98","author":"C Guignabert","year":"2006","unstructured":"Guignabert C, Izikki M, Tu LI et al (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323-1330","journal-title":"Circ Res"},{"key":"20_CR42_20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/jpet.104.081182","volume":"313","author":"I Morecroft","year":"2005","unstructured":"Morecroft I, Loughlin L, Nilsen M et al (2005) Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313:539-548","journal-title":"J Pharmacol Exp Ther"},{"key":"20_CR43_20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1164\/ajrccm\/145.4_Pt_1.793","volume":"145","author":"K Sato","year":"1992","unstructured":"Sato K, Webb S, Tucker A et al (1992) Factors influencing the idiopathic development of pulmonary hHypertension in the fawn hooded rat. Am Rev Respir Dis 145:793-797","journal-title":"Am Rev Respir Dis"},{"key":"20_CR44_20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/rccm.200210-1212OC","volume":"168","author":"E Marcos","year":"2003","unstructured":"Marcos E, Adnot S, Pham MH et al (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168:487-493","journal-title":"Am J Respir Crit Care Med"},{"key":"20_CR45_20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1161\/CIRCULATIONAHA.104.524926","volume":"111","author":"C Guignabert","year":"2005","unstructured":"Guignabert C, Raffestin B, Benferhat R et al (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111:2812-2819","journal-title":"Circulation"},{"key":"20_CR46_20","doi-asserted-by":"publisher","first-page":"L630","DOI":"10.1152\/ajplung.00110.2006","volume":"293","author":"S Laudi","year":"2007","unstructured":"Laudi S, Trump S, Schmitz V et al (2007) Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 293:L630-L6L8","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"20_CR47_20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/01.RES.0000126847.27660.69","volume":"94","author":"E Marcos","year":"2004","unstructured":"Marcos E, Fadel E, Sanchez O et al (2004) Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94:1263-1270","journal-title":"Circ Res"},{"key":"20_CR48_20","first-page":"L46","volume":"266","author":"SL Lee","year":"1994","unstructured":"Lee SL, Wang WW, Lanzillo JJ, Fanburg BL (1994) Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 266:L46-L52","journal-title":"Am J Physiol"},{"key":"20_CR49_20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/01.RES.0000141428.53262.a4","volume":"95","author":"YL Liu","year":"2004","unstructured":"Liu YL, Suzuki YJ, Day RM, Fanburg BL (2004) Rho kinase-induced nuclear translocation of ERK1\/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95:579-586","journal-title":"Circ Res"},{"key":"20_CR50_20","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1161\/CIRCULATIONAHA.108.767558","volume":"117","author":"Y Dempsie","year":"2008","unstructured":"Dempsie Y, Morecroft I, Welsh DJ et al (2008) Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 117:2928-2937","journal-title":"Circulation"},{"key":"20_CR51_20","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0006-2952(03)00556-2","volume":"66","author":"DJ Walther","year":"2003","unstructured":"Walther DJ, Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66:1673-1680","journal-title":"Biochem Pharmacol"},{"key":"20_CR52_20","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1161\/CIRCULATIONAHA.105.591321","volume":"113","author":"S Eddahibi","year":"2006","unstructured":"Eddahibi S, Guignabert C, Barlier-Mur AM et al (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857-1864","journal-title":"Circulation"},{"key":"20_CR53_20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000252210.58849.78","volume":"49","author":"I Morecroft","year":"2007","unstructured":"Morecroft I, Dempsie Y, Bader M et al (2007) Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49:232-236","journal-title":"Hypertension"},{"key":"20_CR54_20","doi-asserted-by":"crossref","first-page":"L282","DOI":"10.1152\/ajplung.1999.277.2.L282","volume":"277","author":"SL Lee","year":"1999","unstructured":"Lee SL, Wang WW, Finlay GA, Fanburg BL (1999) Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol Lung Cell Mol Physiol 277:L282-L291","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"20_CR55_20","doi-asserted-by":"publisher","first-page":"17525","DOI":"10.1074\/jbc.M210465200","volume":"278","author":"YJ Suzuki","year":"2003","unstructured":"Suzuki YJ, Day RM, Tan CC et al (2003) Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J Biol Chem 278:17525-17531","journal-title":"J Biol Chem"},{"key":"20_CR56_20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0891-5849(97)00359-6","volume":"24","author":"SL Lee","year":"1998","unstructured":"Lee SL, Wang WW, Fanburg BL (1998) Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med 24:855-858","journal-title":"Free Radic Biol Med"},{"key":"20_CR57_20","doi-asserted-by":"publisher","first-page":"L111","DOI":"10.1152\/ajplung.00006.2004","volume":"287","author":"JQ Liu","year":"2004","unstructured":"Liu JQ, Folz RJ (2004) Extracellular superoxide enhances 5-HT-induced murine pulmonary artery vasoconstriction. Am J Physiol Lung Cell Mol Physiol 287:L111-L118","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"20_CR58_20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/bjp.2008.310","volume":"155","author":"KM Mair","year":"2008","unstructured":"Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM (2008) Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155:606-616","journal-title":"Br J Pharmacol"},{"key":"20_CR59_20","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1074\/jbc.M604195200","volume":"282","author":"C Guilluy","year":"2007","unstructured":"Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G (2007) Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282:2918-2928","journal-title":"J Biol Chem"},{"key":"20_CR60_20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0092-8674(03)01014-6","volume":"115","author":"DJ Walther","year":"2003","unstructured":"Walther DJ, Peter JU, Winter S et al (2003) Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115:851-862","journal-title":"Cell"},{"key":"20_CR61_20","doi-asserted-by":"publisher","first-page":"15631","DOI":"10.1074\/jbc.M010690200","volume":"276","author":"M Das","year":"2001","unstructured":"Das M, Bouchey DM, Moore MJ, Hopkins DC, Nemenoff RA, Stenmark KR (2001) Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on G protein-mediated activation of mitogen-activated protein kinases. J Biol Chem 276:15631-15640","journal-title":"J Biol Chem"},{"key":"20_CR62_20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.pupt.2006.08.007","volume":"20","author":"HJ Mortimer","year":"2007","unstructured":"Mortimer HJ, Peacock AJ, Kirk A, Welsh DJ P38 MAP (2007) kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation. Pulm Pharmacol Ther 20:718-725","journal-title":"Pulm Pharmacol Ther"},{"key":"20_CR63_20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1152\/japplphysiol.00500.2002","volume":"93","author":"Y Mitani","year":"2002","unstructured":"Mitani Y, Mutlu A, Russell JC, Brindley DN, DeAlmeida J, Rabinovitch M (2002) Dexfenfluramine protects against pulmonary hypertension in rats. J Appl Physiol 93:1770-1778","journal-title":"J Appl Physiol"},{"key":"20_CR64_20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejphar.2006.08.050","volume":"550","author":"GY Rochefort","year":"2006","unstructured":"Rochefort GY, Lemaire MC, Eder V et al (2006) Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension. Eur J Pharmacol 550:149-154","journal-title":"Eur J Pharmacol"},{"key":"20_CR65_20","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1101\/gad.1167003","volume":"17","author":"J Massagu\u00e9","year":"2003","unstructured":"Massagu\u00e9 J (2003) Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev 17:2993-2997","journal-title":"Genes Dev"},{"key":"20_CR66_20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.RES.0000166926.54293.68","volume":"96","author":"XD Yang","year":"2005","unstructured":"Yang XD, Long L, Southwood M et al (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96:1053-1063","journal-title":"Circ Res"},{"key":"20_CR67_20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1161\/01.RES.0000215809.47923.fd","volume":"98","author":"L Long","year":"2006","unstructured":"Long L, MacLean MR, Jeffery TK et al (2006) Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98:818-827","journal-title":"Circ Res"},{"key":"20_CR68_20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1161\/01.RES.0000215809.47923.fd","volume":"98","author":"L Long","year":"2006","unstructured":"Morecroft I, Pang L, Baranowska M et al (2009) In vivo effects of a combined 5-HT1B receptor\/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res In press.","journal-title":"Circ Res"}],"container-title":["Advances in Experimental Medicine and Biology","Membrane Receptors, Channels and Transporters in Pulmonary Circulation"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-60761-500-2_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T12:48:14Z","timestamp":1552394894000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-60761-500-2_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,26]]},"ISBN":["9781607614999","9781607615002"],"references-count":68,"URL":"https:\/\/doi.org\/10.1007\/978-1-60761-500-2_20","relation":{},"ISSN":["0065-2598"],"issn-type":[{"value":"0065-2598","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12,26]]}}}